| 1 |
任成山，王关嵩，钱桂生. 慢性阻塞性肺疾病的成因及其治疗的困惑与希望[J/CD]. 中华肺部疾病杂志(电子版), 2019, 12(2): 127-141.
|
| 2 |
Global Initiative for Chornic Obstructive Lung Disease 2020 Report[R]. 2020.
|
| 3 |
中华医学会，中华医学会杂志社，中华医学会全科医学分会，等. 慢性阻塞性肺疾病基层诊疗指南(2018年)[J]. 中华全科医师杂志，2018, 17(11): 856-870.
|
| 4 |
施 毅. 重视非粒细胞缺乏患者侵袭性肺曲霉病的临床诊治[J]. 上海医药，2014, 35(9): 15-19.
|
| 5 |
胡艳艳，张睢扬. 慢性阻塞性肺疾病与肺曲霉菌感染的研究进展[J/CD]. 中华肺部疾病杂志(电子版), 2014, 7(2): 220-223.
|
| 6 |
刘又宁，余丹阳，孙铁英，等. 中国1998年至2007年临床确诊的肺真菌病患者的多中心回顾性调查[J]. 中华结核和呼吸杂志，2011, 34(2): 86-90.
|
| 7 |
施 毅. 侵袭性肺真菌病诊治的再认识[J]. 中华结核和呼吸杂志，2011, 34(2): 83-85.
|
| 8 |
Chris K, David WD. The clinical spectrum of pulmonary aspergillosis[J]. Thorax, 2015, 70(3): 270-277.
|
| 9 |
Claire D, Aurélie C, Emilie F, et al. Putative invasive pulmonary aspergillosis in critically ill patients with chronic obstructive pulmonary disease: a matched cohort study[J]. Crit Care, 2015, 19: 421.
|
| 10 |
Ritesh A, Basanta H, Dheeraj G, et al. Aspergillus hypersensitivity in patients with chronic obstructive pulmonary disease: COPD as a risk factor for ABPA? [J]. Med Mycol, 2010, 48(7): 988-994.
|
| 11 |
Bulpa P, Dive A, Sibille Y. Invasive pulmonary aspergillosis in patients with chronic obstructive pulmonary disease[J]. Eur Respir J, 2007, 30(4): 782-800.
|
| 12 |
Fabio ST, Anne-Marie Van den A, Pierre B, et al. Epidemiology of invasive aspergillosis in critically ill patients: clinical presentation, underlying conditions, and outcomes[J]. Critical care (London, England), 2015, 19(1): 7.
|
| 13 |
Tejerina EE, Abril E, Padilla R, et al. Invasive aspergillosis in critically ill patients: An autopsy study[J]. Mycoses, 2019, 62(8): 673-679.
|
| 14 |
Guinea J, Torres-Narbona M, Gijǘn P, et al. Pulmonary aspergillosis in patients with chronic obstructive pulmonary disease: incidence, risk factors, and outcome[J]. Clin Microbiol Infect, 2010, 16(7): 870-877.
|
| 15 |
Cornillet A, Camus C, Nimubona S, et al. Comparison of epidemiological, clinical, and biological features of invasive aspergillosis in neutropenic and nonneutropenic patients: A 6-year survey[J]. Clin Infect Dis, 2006, 43(5): 577-584.
|
| 16 |
陈瑞英，靳建军，欧阳松云，等. 非中性粒细胞缺乏患者发生侵袭性曲霉病的危险因素、临床特征及预后分析[J]. 中国实用医药，2008, 3(15): 48-50.
|
| 17 |
Denning DW, Pleuvry A, Cole DC, et al. Global burden of chronic pulmonary aspergillosis as a sequel to pulmonary tuberculosis[J]. Eur Respir J, 2013, 41(3): 621-626.
|
| 18 |
Denning DW, Cadranel J, Beigelman-Aubry C, et al. Chronic pulmonary aspergillosis: rationale and clinical guidelines for diagnosis and management[J]. Eur Respir J, 2016, 47(1): 45-68.
|
| 19 |
李 培，苏 欣，施 毅. 慢性肺曲霉病基础疾病108例回顾性分析[J]. 中国呼吸与危重监护杂志，2018, 17(4): 348-353.
|
| 20 |
Hammond EE, McDonald CS, Vestbo J, et al. The global impact of Aspergillus infection on COPD [J]. BMC pulmonary med, 2020, 20(1): 241.
|
| 21 |
David L, Khaled Al-S, Pippa JN, et al. Predictors of mortality in chronic pulmonary aspergillosis[J]. Eur respir J, 2017, 49(2): 1601062.
|
| 22 |
安勇鹏，雷军旗. 慢性阻塞性肺疾病合并侵袭性肺曲霉菌病的危险因素分析[J]. 中国临床新医学，2018, 11(12): 1240-1242.
|
| 23 |
吴 克，赵丽敏. 慢性阻塞性肺疾病合并侵袭性肺曲霉菌病临床分析[J]. 医药论坛杂志，2019, 40(2): 12-15.
|
| 24 |
吴付梅，程 华，秦娜娜，等. 慢性阻塞性肺疾病合并临床诊断侵袭性肺曲霉病40例回顾性分析[J]. 世界最新医学信息文摘(连续型电子期刊), 2019, 19(66): 198-199.
|
| 25 |
胡小燕，王卓萍，陈小英. 慢性阻塞性肺疾病合并侵袭性肺曲霉菌病的多因素logistic回归分析[J]. 中国基层医药，2020, 27(8): 913-916.
|
| 26 |
张 蕾，杨 青，赵 钊，等. 慢性阻塞性肺疾病合并侵袭性肺曲霉病的临床特征及危险因素分析[J]. 中华临床感染病杂志，2020, 13(2): 113-118.
|
| 27 |
任之栋，张 巧，张玉江，等. 慢性阻塞性肺疾病合并慢性肺曲霉菌病的高危因素及临床特征分析[J/CD]. 中华肺部疾病杂志(电子版), 2021, 14(1): 11-16.
|
| 28 |
He Q, Li HX, Rui YW, et al. Pentraxin 3 gene polymorphisms and pulmonary aspergillosis in chronic obstructive pulmonary disease patients[J]. Clin Infect Dis, 2018, 66(2): 261-267.
|
| 29 |
Shah MM, Hsiao EI, Kirsch CM, et al. Invasive pulmonary aspergillosis and influenza co-infection in immunocompetent hosts: case reports and review of the literature[J]. Diagnostic Micro Infect Dis, 2018, 91(2): 147-152.
|
| 30 |
Bulpa P, Duplaquet F, Dimopoulos G, et al. Invasive pulmonary aspergillosis in chronic obstructive pulmonary disease exacerbations[J]. Semin Respir Crit Care Med, 2020, 41(6): 851-861.
|
| 31 |
Khaled Al-S, Eavan GM, Julie M, et al. Characterisation of fatigue and its substantial impact on health status in a large cohort of patients with chronic pulmonary aspergillosis (CPA) [J]. Respir Med, 2016, 114: 117-122.
|
| 32 |
Thomas FP, George RT, David WD, et al. Practice guidelines for the diagnosis and management of aspergillosis: 2016 Update by the infectious diseases society of america[J]. Clin Infect Dis, 2016, 63(4): e1-e60.
|
| 33 |
杨仁恒. 慢性阻塞性肺疾病并侵袭性肺曲霉菌病患者的临床表现及胸部CT表现分析[J]. 实用心脑肺血管病杂志，2016, 24(1): 105-107.
|
| 34 |
程 利，杨家友，陈月华，等. 慢性阻塞性肺疾病合并肺曲霉菌感染双源薄层CT图像特征及预后分析[J]. 中国CT和MRI杂志，2019, 17(11): 45-47.
|
| 35 |
Silke S, Rosemary AB, Richard CB, et al. British society for medical mycology best practice recommendations for the diagnosis of serious fungal diseases[J]. The Lancet Infect Dis, 2015, 15(4): 461-474.
|
| 36 |
Guinea J, Torres-Narbona M, Gijón P, et al. Pulmonary aspergillosis in patients with chronic obstructive pulmonary disease: incidence, risk factors, and outcome[J]. Clin Microbiol Infect, 2010, 16(7): 870-877.
|
| 37 |
Masahito K, Yoshinobu K, Susumu G, et al. Diagnosis of pulmonary aspergillosis using optical brighteners[J]. Eur Respir J, 2000, 15(2): 407-411.
|
| 38 |
Zhang SZ, Wang SB, Wan Z, et al. The diagnosis of invasive and noninvasive pulmonary aspergillosis by serum and bronchoalveolar lavage fluid galactomannan assay[J]. Biomed Res Int, 2015, 2015: 943691.
|
| 39 |
Guitard J, Sendid B, Thorez S, et al. Evaluation of a recombinant antigen-based enzyme immunoassay for the diagnosis of noninvasive aspergillosis[J]. J Clin Microbiol, 2012, 50(3): 762-765.
|
| 40 |
Launes C, Esteban E, Balaguer M, et al. Comparison of six aspergillus-specific IgG assays for the diagnosis of chronic pulmonary aspergillosis (CPA)[J]. J Infect, 2016, 72(2): 240-249.
|
| 41 |
Kappe R, Rimek D. Antibody detection in patients with invasive aspergillosis[J]. Mycoses, 2004, 47(Suppl 1): 55-59.
|
| 42 |
Page ID, Richardson M, Denning DW. Antibody testing in aspergillosis-quo vadis？[J]. Med Mycol, 2015, 53(5): 417-439.
|
| 43 |
Ma X, Wang K, Zhao X, et al. Prospective study of the serum Aspergillus-specific IgG, IgA and IgM assays for chronic pulmonary aspergillosis diagnosis[J]. BMC Infect Dis, 2019, 19(1): 694.
|
| 44 |
Tomer A, Itzhak L, Hannah S, et al. Diagnostic accuracy of PCR alone compared to galactomannan in bronchoalveolar lavage fluid for diagnosis of invasive pulmonary aspergillosis: a systematic review[J]. J Clin Microbiol, 2012, 50(11): 3652-3658.
|
| 45 |
Ascioglu S, Rex JH, Pauw B de, et al. Defining opportunistic invasive fungal infections in immunocompromised patients with cancer and hematopoietic stem cell transplants: an international consensus[J]. Clin Infect Dis, 2002, 34(1): 7-14.
|
| 46 |
Ben DP, Walsh TJ, Peter DJ, et al. Revised definitions of invasive fungal disease from the european organization for research and treatment of cancer/invasive fungal infections cooperative group and the national institute of allergy and infectious diseases mycoses study group (EORTC/MSG) consensus group[J]. Clin Infect Dis, 2008, 46(12): 1813-1821.
|
| 47 |
Vandewoude KH, Blot SI, Depuydt P, et al. Clinical relevance of Aspergillus isolation from respiratory tract samples in critically ill patients[J]. Critical care (London, England), 2006, 10(1): R31.
|
| 48 |
Stijn IB, Fabio ST, Anne-Marie Van den A, et al. A clinical algorithm to diagnose invasive pulmonary aspergillosis in critically ill patients[J]. Am J Respir Crit Care Med, 2012, 186(1): 56-64.
|
| 49 |
Bulpa P, Bihin B, Dimopoulos G, et al. Which algorithm diagnoses invasive pulmonary aspergillosis best in ICU patients with COPD？[J]. Eur Respir J, 2017, 50(3): 1700532.
|
| 50 |
Huang L, He HY, Jin JJ, et al. Is Bulpa criteria suitable for the diagnosis of probable invasive pulmonary aspergillosis in critically ill patients with chronic obstructive pulmonary disease? A comparative study with EORTC/MSG and ICU criteria[J]. BMC Infect Dis, 2017, 17(1): 209.
|